These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23613973)

  • 1. Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010.
    Tseng HK; Liu CP; Ho MW; Lu PL; Lo HJ; Lin YH; Cho WL; Chen YC;
    PLoS One; 2013; 8(4):e61921. PubMed ID: 23613973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA; Arthur I; Merritt A; Leung M
    Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.
    González GM; Casillas-Vega N; Garza-González E; Hernández-Bello R; Rivera G; Rodríguez JA; Bocanegra-Garcia V
    Folia Microbiol (Praha); 2016 Jan; 61(1):51-6. PubMed ID: 26109075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
    Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
    Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017.
    Fang LF; Zhang PP; Wang J; Yang Q; Qu TT
    Braz J Infect Dis; 2020; 24(1):7-12. PubMed ID: 31870760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular typing and antifungal susceptibility of clinical isolates of Cryptococcus neoformans and Cryptococcus gattii species complexes from the National Invasive Fungal Surveillance Network of Uruguay.
    Puime CA; Bórmida V; Pan D
    Med Mycol; 2023 Jul; 61(7):. PubMed ID: 37336574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR-fingerprinting.
    Olivares LR; Martínez KM; Cruz RM; Rivera MA; Meyer W; Espinosa RA; Martínez RL; Santos GM
    Med Mycol; 2009 Nov; 47(7):713-21. PubMed ID: 19888804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-locus sequence typing reveals genotypic similarity in Nigerian
    Chidebelu PE; Nweze EI; Meis JF; Cogliati M; Hagen F
    J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34665109
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil.
    Herkert PF; Meis JF; Lucca de Oliveira Salvador G; Rodrigues Gomes R; Aparecida Vicente V; Dominguez Muro M; Lameira Pinheiro R; Lopes Colombo A; Vargas Schwarzbold A; Sakuma de Oliveira C; Simão Ferreira M; Queiroz-Telles F; Hagen F
    J Med Microbiol; 2018 Apr; 67(4):560-569. PubMed ID: 29461182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
    J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of molecular types and genetic heterogeneity of Cryptococcus neoformans and C. gattii in Malaysia.
    Tay ST; Lim HC; Tajuddin TH; Rohani MY; Hamimah H; Thong KL
    Med Mycol; 2006 Nov; 44(7):617-22. PubMed ID: 17071555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
    Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
    Espinel-Ingroff A; Chowdhary A; Cuenca-Estrella M; Fothergill A; Fuller J; Hagen F; Govender N; Guarro J; Johnson E; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; Trilles L; Kidd S; Turnidge J
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3107-13. PubMed ID: 22391546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.